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ABSTRACT
Sanghvi, Saagar Kamlesh. M.S. Department of Neuroscience, Cell Biology &
Physiology, Wright State University 2012. Effect of Rat Strain and Stereotactic
Coordinates on Infarct Volume.
Ischemic stroke makes up 87% of all hospital-admitted stroke cases annually; the primary
treatment for these cases is intravenous administration of tPA within a 3.5 hour window
from stroke onset. A long-term delayed ischemic stroke treatment proposed by this study
was a combination of the pharmaceuticals Fluoxetine (SSRI), Simvastatin (statin), and
ascorbic acid (Vitamin C). 51 adult rat subjects (10-12 months of age; 44 Sprague
Dawley, 7 Long Evans) were given a combination of the drugs for 31 days. Drugs were
given through voluntary oral administration via sugar cookie-dough balls to reduce
inhibition of neurogenesis through stress-related glucocorticoid production. Drug
combinations were as follows: FSA - 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin and 20
mg/kg ascorbic acid; FS - 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin; and the vehicle
control. Endothelin-induced cortical stroke was administered using 2 different set of
coordinates relative to bregma: Group 1 - (AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm;
ML: -2.5 mm); Group 2 - (AP: 0.0 mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm). To
analyze functional deficit, rats were subject to Montoya Staircase functional test once
pre-stroke and twice post-stroke, and the Forelimb Asymmetry functional test once prestroke and thrice post-stroke. Results showed that Long Evans rats sustain a significantly
larger infarct volume compared to Sprague Dawley rats using Group 2 coordinates;
Group 1 cortical injection coordinates produced a larger infarct than Group 2 coordinates
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in FSA Sprague Dawley rats; drug treatment showed no effect on total infarct volume,
however, this may be attributed to use of generic fluoxetine in Group 2 Sprague Dawley
rats.
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INTRODUCTION
Problem: Stroke
As the 2nd leading cause of death in the world surpassed only by ischemic heart
disease, Cerebrovascular disease in the US claims 133,000 lives every year (NSA, 2012).
Almost 800,000 strokes will occur nationwide this year alone – once every 40 seconds,
causing a fatality approximately every 4 minutes (NSA, 2012). Stroke is defined as an
acute condition: blood supply to the brain is altered in affected areas due to a vascular
blockage or hemorrhaging vessel, and the resulting tissue ischemia can cause cell death
within minutes of stroke onset. However, with 7,000,000 adult stroke survivors – twothirds of who endure some type of stroke-related disability everyday – the effects of
stroke are chronic (VL, 2012). Visual impairments, paralysis, aphasia, and other sensory
and motor deficits can result from brain tissue damage. American patients' average direct
cost of care for 90 days post-stroke is greater than $15,000, with additional costs from
rehabilitation and preventative medications that can last years. The US currently spends
$43 billion on stroke a year (Di Carlo, 2009). Considering three-fourths of all stroke
patients are older than 65 years, a population expected to grow 200% worldwide over the
next 30 years, the healthcare system itself faces a long-term economic problem in
addition to the growing human cost (AHA, 2012).
What is a stroke and how is it treated?
There are two defined types of stroke– ischemic and hemorrhagic. Ischemic
strokes account for the vast majority (87%) of all stroke cases (AHA, 2012). This
1

condition results from gradual atherosclerotic plaque and fatty-acid deposit accumulation
in a brain blood vessel. These blockages either originate at the site (thrombotic stroke) or
are transported from another location in the body vasculature (embolic stroke). Risk
factors for an ischemic attack include hypertension, high cholesterol, diabetes, obesity,
alcoholism, and conditions such fibromuscular dysplasia and atrial fibrillation (NSA,
2012). Less common hemorrhagic strokes result from a blood vessel rupture in or on the
surface of the brain; treatments associated with this condition promote blood coagulation
and reducing brain pressure.
The primary treatment for an ischemic stroke attack is administration of
recombinant Tissue Plasminogen Activator (rt-PA) within a 3.5-hour window of stroke
onset. tPA, a natural human enzyme found in endothelial cells lining blood vessels,
activates plasminogen in order to dissolve blood clots. rt-PA is most commonly injected
through a vein in the arm, but can also be delivered directly to the infarct site via catheter.
Up to 70% of hospital stroke admissions are for ischemic stroke; however, only 3.5 to 8%
of these patients are able to receive the rt-PA clot-buster within the 3.5-hour
administration window. Most admitted ischemic stroke patients must seek an alternate
method of treatment (Mayo Clinic, 2010).
The vast majority of diagnosed ischemic stroke patients are prescribed aspirin for
for its blood-thinning effect, primarily to prevent another stroke. Other blood-thinning
drugs such as warfarin (Coumadin), heparin and clopidogrel (Plavix) are also options for
preventative stroke treatment, but the presence of aneurysms or other risk factors for
hemorrhagic stroke must be taken heavily into consideration (Mayo Clinic, 2010).
Invasive surgical procedures such as stent angioplasties and carotid endarterectomies are
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useful only for a small percentage of stroke patients. Most stroke patients have numerous
surgical complications and therefore increased probabilities of triggering another
ischemic attack, weak vessels hemorrhaging, or recurrent vessel stenosis. Considering
that 25% of victims will have a repeat incidence within 5 years, and more than 50% of all
ischemic stroke victims will die in 8 years, a need for an effective long-term stroke
treatment aside from prescribing aspirin remains (ISC, 2012).
A Drug-Cocktail for Delayed Treatment of Ischemic Stroke
A treatment model that increases the window of time available to administer rtPA or aides in developing a long-term treatment solution needs to either diminish the
onset of ischemic stroke or curb the effects of stroke after onset. Treatment strategies
examining various elements of the ischemic stroke cascade, including calcium channels
and glutamate receptors, have either been unsuccessful or are currently undergoing trials
(Shabitz, 2006). A probable strategy for treating neural sensory and motor deficits caused
by stroke, however, can be related to curing the damaged brain tissue itself. Growth of
neurons and glial cells have been linked to various growth factors that may also play a
role in repairing damaged tissue (Allen, 2006). Up-regulating factors involved in
neurogenesis or growth factor production may play a role in treating brain deficits related
to stroke.
Two germinal niches have been identified as regions of neurogenesis: the
subventricular zone (SVZ) and the subgranular zone (SGZ). The SVZ is found adjacent
to the lateral ventricles of the forebrain (see Figure 1), and the SGZ is found within the
dentate gyrus of the hippocampus. Self-renewing, multipotent cells that have been shown
to create various neural cells are found in both regions; however, the SVZ is the largest
3
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Figure 1.

shown to be the largest

(A) Rat brain: Neurogenic Centers, Rostral Migratory Stream leading to
olfactory bulb
Image from Scientopia.org
(B) Human Brain: Subventricular Zone (SVZ), adjacent to the lateral
ventricles
Image from Oscar Arias-Carrión, 2008

neurogenic niche in the adult brain (Quinoneshinojosa, 2007).
The subventricular zone (SVZ) contains multipotent neural stem cells (type B
cells) that have been
identified as the neural
progenitor cell (GonzalesPerez, 2012). This selfrenewing astrocytic type B
cell can then generate selfrenewing “transitamplifying” progenitor
cells (type C cells) (see
Figure 2). These type C
Figure 2. Self-renewing multipotent neural stem cells (type B) can differentiate into
transit-amplifying cells (type C). Self-renewing type C cells can differentiate into
migrating neuroblasts (type A).
Image from Gonzales-Perez, 2012
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cells may then differentiate into various migrating neuroblasts (type A cells), that develop
into end cells such as neurons, oligodendrocytes, and astrocytes. Type B cells are made
up of Type B1 and Type B2 astrocytes. Type B1 cells associate closely with the
ependymal layer through adherens and gap junctions, and the brain parenchymal blood
vessels and basal lamina. Their apical processes extend to the ventricular surface
(Gonzales-Perez, 2012). These associations have suggested that type B cells may play a
role in neurogenesis through direct interaction and supporting growth. The newly formed
type A neuroblasts migrate to the olfactory bulb along the rostral migratory pathway.
Type B1 cells express molecular markers associated with their astrocytic morphology, a
few of which are glial fibrillary acidic protein (GFAP), nestin, and vimentin. Type C cells
can be identified using epidermal growth factor receptors (EGFR). Type A-cell
neuroblasts can be identified with doublecortin (Zhang, 2004).
Growth factors associated with neurogenesis include epidermal growth factor
(EGF) and the family of neurotrophins, specifically brain-derived neurotrophin (BDNF).
EGF has been shown to support proliferation of SVZ neural progenitors such as type B1
cells (Gonzales-Perez, 2009); BDNF has been shown to support existing neurons while
promoting neurogenesis and synaptogenesis (Mattson, 2008).
The primary difference between the human and rodent subventricular zone is that
in humans, the 2nd SVZ layer (hypocellular gap) is devoid of cell bodies, and 3rd layer
astrocytes are organized as a ribbon of GFAP+ cells that do not contact the ependymal
layer (see Figure 3). In both species, the SVZ 1st layer is made of multi-ciliated
ependymal cells that regulate substance such as cerebrospinal fluid at the ventricular
surface. The 4th layer has myelin sheaths that act as a transition zone into the brain
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parenchyma (GonzalesPerez, 2012).
A drug cocktail
developed to repair
damaged brain tissue can
work through promoting
neurogenesis or the
production of growth
factors shown to support
Figure 3. 4 layers of the subventricular zone (I, II, III, IV)
Image from Gonzales-Perez, 2012

neurogenesis. Statins
have been commonly

used for reducing cholesterol levels in preventing various artery diseases; studies have
also established pleiotropic effects of statins which include inducing neurogenesis and
synaptogenesis in the hippocampal dentate gyrus (Lu et al, 2007; Chen et al, 2003) upregulation of endothelial nitric oxide synthase (eNOS) and tPA activity, and increased
levels of brain-derived neurotrophic factor (BDNF) in the ischemic boundary zone after
stroke. After phosphorylation and subsequent activation of eNOS, statins have been
shown to increase the amount of NO, though the exact mechanism is not fully understood
(Datar et al, 2010). eNOS has also been shown to up-regulate BDNF (Wu et al, 2006).
Selective-serotonin re-uptake inhibitors (SSRIs) have been used to treat
depression for years, but have recently been associated with promoting neurogenesis and
BDNF production. Studies have shown a marked reduction in neurogenesis when cells
are damaged within the dentate gyrus in rodents. Chronic treatment with Fluoxetine
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Figure 4. (A) Fluoxetine; (B) Simvastatin; (C) Ascorbic Acid
specifically has been proven to up-regulate neurogenesis in the hippocampus and the
production of BDNF in rodent studies (Ploughman et al, 2009). Upregulation of BDNF is
linked to serotonin binding to 5-HT subtype receptors in both the SVZ and SGZ (Benasr
et al, 2003). Chollet's recent FLAME study (2011) has shown enhanced motor recovery
in ischemic stroke patients after chronic fluoxetine treatment. Patient subjects were given
20 mg fluoxetine to take orally for 90 days. The treatment was started 5-10 days after
stroke and was coupled with physiotherapy.
The drug cocktail in this study developed for delayed post-stroke treatment
included Simvastatin (statin) and Fluoxetine (SSRI). The final component added was
Ascorbic acid (Vitamin C), an antioxidant (see Figure 4). Ascorbic acid has been shown
to enhance the effects of SSRIs that are otherwise very sensitive oxidative degradation
(Idayu et al, 2010). Furthermore, ascorbic acid increases the effectiveness of statins by
supporting the endothelial eNOS system that up-regulates BDNF (Chen et al, 2005). The
majority of neurogenesis studies conducted have focused on the SGZ hippocampal niche.
Therefore this study will concentrate on the more active SVZ neurogenic niche in rats in
post-stroke studies.
Stroke and Animal Model
The Middle Cerebral Artery Occlusion (MCAo) is the most common focal
7

ischemia model used in young rodents (Windle et al, 2006). A modern approach to create
this occlusion is by inserting an intraluminal suture through the external carotid artery,
through the internal carotid artery, and up to the point of MCA opening. Another method
involves a craniectomy, electrocoagulation of the MCA, and a final cut of the artery to
insure occlusion (Macrae et al, 2006). The use of aneurysm clips allows for occlusion
followed by immediate vascular reperfusion upon removal. The injury caused by
immediate reperfusion is not completely analogous to reperfusion injury in post-stroke
patients, which occurs over a timescale of hours. Other disadvantages of MCAo include:
relatively variability in the amount of injury caused, the ischemic injury sometimes does
not affect the motor cortex, or other arteries become inadvertently blocked with or
without MCAo therefore not representing a true MCA infarct (Liu, 2011). Inadvertently
blocked MCA adjacent arteries can result in feeding difficulties that will affect food and
drug intake, as well as deterioration of long-term health (Windle et al, 2006). These
factors can heavily influence outcomes of motor deficit studies.

Figure 5. A schematic representation of the various stroke models presented, induced
by endothelin-1
Image from Windle et al, 2006
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A less invasive method of inducing stroke are various ways of applying
Endothelin-1 (ET-1), a potent vasoconstrictor that can produce ischemic injury when
injected directly into brain tissue. ET-1 injection has shown a more consistent injury
profile (Soleman et al, 2010) as well as more consistent MCA infarcts (Windle et al,
2006). ET-1 also allows for reperfusion injury to occur over several hours as opposed to
clips and sutures that allow for reperfusion almost instantly after removal, thus better
mimicking a human stroke (Windle et al, 2006). The amount of stroke injury can adjusted
comparison to MCA infarcts (see Figure 5). Though the topical injection produces more
concentrated lesions than the
intracortical injection, the
intracortical method creates
lesions large enough for viable
motor deficits. The “success
rate” in this study was gauged
by the number of animals that
survived stroke induction

Figure 6. Cortical stroke induced by ET-1 resulted in the
highest Montoya Staircase deficit both 1 week (A) and 1
month (B) post-surgery.

surgery, coupled with a
minimum of 20% forelimb
function deficit in the
Montoya Staircase behavioral
test. The success rate was
highest for intracortical
injection (up to 91%

Figure 7. Cortical stroke induced by ET-1 resulted in the
highest % of ipsilateral function 1 week post-surgery (A),
and remained high 1 month post-surgery (B)
9

depending on dosage) in comparison to both MCAo (50%) and topical injection (75%).
The Intracortical injection method is also shown to maintain the highest percentage of
ipsilateral forelimb function 1-week post-surgery and remains significantly higher than
the contralateral limb 1-month post-surgery. Also, the percentage of Montoya Staircase
deficit is highest in the intracortical injection subjects than other methods 1-month post
surgery. (see Figures 6 & 7). Therefore, intracortical injection using Endothelin-1
causing a cortical stroke (Windle et al, 2006) was the developed stroke induction model
modified for use by our
laboratory.
In developing a viable
animal model, adult rats were
chosen for the study. This is
because studies in younger rats
have shown a near-linear increase
in motor recovery in control
models – adults rats do not
display such rapid recovery rates
(see Figure 8) (Weissner et al,
2003). Cultivating this rate of
improvement in an adult rat could
be correlated to an increase in
neurogenesis. Additionally,

Figure 8. Control models show rapid initial
recovery in motor function in young rats
Graphs taken from Weissner et al, 2003

human stroke occurs most often in those above age 55, and adult rat subjects around 1
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year old (2 year life-span) would have a greater correlation to the human stroke model
(Cameron et al, 1982). This is another reason MCAo could not be used; adult rats do not
sustain a neurogenic growth rate large enough to recover from such a large injury.
Sprague Dawley and Long-Evans rats have traditionally been used as Montoya
Staircase subjects. Sprague Dawley rats were proven to be most successful in achieving
pre-stroke training criteria when compared to Wistar and Long-Evans rats. Female rats
were used in the study because they fulfill weight limit criteria for commercial Montoya
Staircase models – 400 grams). Female weight range is 250-300 grams while males range
between 450-520 grams.
Drug Delivery Method
An administration method had to be developed to effectively deliver the
Fluoxetine, Simvastatin, and Ascorbic acid drug cocktail to rats. Because drugs were to
be delivered into the bloodstream daily, an administration method that minimized stress
was also essential. The physiological effects of stress include anxiety, hypertension and
other cardiovascular effects, increased susceptibility to infection and other
immunological effects, and increased levels of glucocorticoids released in the
bloodstream (NIMH, 2012). Glucocorticoids, especially corticosterone, have been shown
to inhibit neurogenesis among other neurophysical effects (Cameron et al, 1999).
A common method for daily administration of drugs is through subcutaneous
injection. A recent study compared the effects on corticosteroid levels of subcutaneous
injection versus oral administration of buprenorphine (Goldkuhl et al, 2008). The results
showed that oral administration of buprenorphine significantly reduced corticosteroid
levels while subcutaneous injection subjects showed no reduction in these hormone
11

levels.
Oral administration through oral gavage is a commonly used method and has been
shown to be an effective method of drug delivery. This method, however, has been
shown to produce esophageal injury as well as restraint related stress during
administration (Atcha et al, 2010). Studies have shown that voluntary oral administration
causes less distress and decreased glucocorticoid levels in comparison to using an oral
gavage. This is especially pertinent for administering the stroke drug cocktail for this
study because medications must be delivered into the bloodstream daily.
Oral administration through syringe or jello (Flecknell et al, 1999) are useful for
medication that dissolve easily in an aqueous solution or are liquid to begin with. The
drug cocktail of Fluoxetine, Simvastatin, and Ascorbic acid, however, is lipid soluble
solid. Therefore, an effective vehicle for administration was found in dissolving the
powder substance into Pillsbury sugar cookie-dough. Sugar cookie-dough also chosen
because it was shown to completely absorb lipid-soluble drugs, it could be handled
easily, and be reliably digested by rodent subjects. Alternative drug-vehicles, such as
food wafers (Ferguson et al, 2009) were not as reliable throughout the process, from
handling to drug delivery. Sprague Dawley rats were shown to especially digest the
cookie-dough with the least failure when compared to other rat strains. In this study, high
performance liquid chromatography (HPLC) analysis showed serum levels of
norfluoxetine and fluoxetine 2-4 hours after drug administration (Corbett et al, 2012).
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MATERIALS AND METHODS
Experimental Design
A total of 51 rat subjects – 44 Sprague Dawley, 7 Long-Evans – were used for
stroke treatment testing. These two adult rat stocks (10-12 months of age) were chosen
because of their efficacy in completing Montoya Staircase training (see below).
2 drug combination vehicles and 1 vehicle control, making 3 total drug treatment
groups, were tested over a 1-month period; Drug combination 1: 5 mg/kg fluoxetine, 0.5
mg/kg simvastatin and 20 mg/kg ascorbic acid (FSA); Drug combination 2: 5 mg/kg
fluoxetine, 0.5 mg/kg simvastatin (FS); Vehicle control (C).
During the endothelin-induced stroke (described below), 2 different sets of
cortical injection coordinates were used with two injection site in each set; Group 1: (AP:
0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm); Group 2: (AP: 0.0 mm, ML: 2.5mm) and (AP +2.3; ML -2.5 mm).
Animal subjects completed Forelimb Asymmetry (described below) and Montoya
Staircase training within a maximum time of 2 weeks. 20 to 26 hours after stroke
induction, the first drug vehicle was given through voluntary oral administration.
Treatment continued daily until 31 days post-stroke, at which time the animal was
euthanized. Rats were subject to the Forelimb Asymmetry functional test at 3, 16, and 28
days post-stroke induction. Rats were subject to the Montoya Staircase functional test on
post-stroke days 8-10 and 29-31.
Daily conditions: Rats had ad libitum access to food and water except during
	
  

13	
  

Montoya Staircase training and functional testing post-stroke. Subjects were housed in
12-hour light/12-hour dark conditions, which were approved, along with all other animal
procedures, by the IACUC at Wright State University.
Endothelin-Induced Cortical Stroke
Procedure prior to Endothelin Injection
Anesthesia was induced by inhalation through rodent facial mask of 5%
isoflurane; concentration was maintained at 2-2.5% throughout the stroke-induction
surgery. Isoflurane was selected because animal subjects reach the surgical plane for
anesthesia and recover the quickest from this inhalant in comparison to injectable
anesthetics such as ketamine. Concentration levels are also more easily changed using the
inhalant anesthetic versus injectable.
The rat's head was mounted in a
stereotactic apparatus that utilizes
non-traumatic ear bars to reduce
stress. Puralube ointment was applied
to the eyes to maintain moisture and
the head was shaved. The surgical
site at the top of skull was shaved and
then cleaned in a 3-step process using
provoiodine, then 70% ethanaol, and

Figure	
  9.	
  Orientation	
  of	
  coordinate	
  axes	
  
relative	
  to	
  Bregma	
  

finally provoiodine again to insure a clean incision and surgical procedure (as according
to Wright State Animal-Care Protocol). The analgesic Bupivicaine (0.25%) was applied
drop-wise to the midline incision in the skin. Unlike most alternative analgesics,
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Bupivicaine acts locally without pervading the systemic circulation. To drill 2 holes in
the skull, a 0.9 mm burr micro-drill (Fine Science Tools) was used. The drilling
coordinates for two holes in the skull relative to bregma for Group 1 were (AP: 0.0 mm,
ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm), and coordinates for Group 2 were (AP:
0.0 mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm) (see Figure 9).
Endothelin Injection and Post-Injection Procedure
Using a 10 microliter Hamilton syringe, 1 microliter of endothelin solution was
injected at a depth of 2.3 mm (Long Evans) or 2.0 mm (Sprague Dawley) into the drilled
holes. The endothelin solution (Human and Porcine ET-1, EMD Chemicals) was
maintained at a concentration of 400 pmoles/microliter and the injection took place over
a 2-minute time period (modified from
procedures described in Windle et al, 2006).
Vicryl resorbable sutures resealed the incision,
and the surgical area was again coated with
provoiodine. Analgesics were not administered
post-surgery as they have been demonstrated to
promote or inhibit growth of neural progenitors
(Hoehn et al, 2005; Sasaki et al, 2003; Sargeant

Figure	
  10.	
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  rolled-‐up	
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et al, 2008).
Voluntary Oral Drug Administration
Purchased pharmaceuticals of Simvastatin (80 mg tablet) and Fluoxetine HCl (20
mg capsule) were used as the primary components for stroke drug treatment. The amount
of active ingredients within each pharmaceutical correlates to the total drug weight by a
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specific correction factor; this factor accounts for the amount of “fill” compounds present
that are inert. For examples, the correction factor for Simvastatin is 10X, and for
Fluoxetine it is 7.5X using generic drugs – correction factor was recalculated upon every
new drug purchase. Ascorbic acid (Vitamin C, Fluka) was purchased and administered in
its pure form. Encapsulated drugs were dumped directly onto the weighing dish; pills
were first pulverized before weighing.
All drugs were encapsulated within a 4 gram Pillsbury sugar cookie-dough “ball”,
the drug vehicle for voluntary oral administration. A drug-free vehicle was given to the
rats starting 2 days before surgery, and again after stroke-induction surgery to acclimate
them to this novel food. Preparation for the cookie-dough “ball” went as follows: 1) the
4-gram balls were prepared with gloved hands (see Figure 10); 2) a depression within
each ball was made; 3) the appropriate weight of drugs relative to animal's body mass
was placed within the depression (Step 3 was skipped for control rat subjects); 4) the
cookie-dough balls are wrapped and re-rolled up, ensuring a homogenous solid
containing all medication is created. These cookie-dough balls are placed in each rat cage
at approximately noon each day of the 31-day stroke treatment regimen. Most often, the
drug-vehicle was consumed within 10 minutes of presentation. On occasion, consumption
time would last longer; therefore, the petri-dish in which the drug-vehicle is presented on
was allowed to sit for 1 full day before being replaced. Remaining drug vehicle that goes
unconsumed is counted against the total medication consumed; 3 or more days of failing
to fully consume the drug vehicle was criteria for exclusion from the study.
Montoya Staircase Functional Test
The training period for the Montoya Staircase can last a maximum for 2 weeks.
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The apparatus was set up as shown (see
Figure 11) with three 50 mg sucrose pellets
on each well for 7 levels of the staircase
(both on the right and left sides). Sucrose
pellets were painted with maple extract and
allowed to dry prior to placement within the
apparatus. Training sessions were for a 15-

Figure	
  11.	
  Montoya	
  Staircase	
  
functional	
  test	
  

minute period, once a day, in the 12-hour dark phase. The final 3 days of training were
used to create the pre-stroke baseline; of these 3 days, the day in which the most pellets
were retrieved is used. If multiple days showed the same maximum number of pellets
received but varied between forelimbs, the results were averaged. During this time,
animal subjects receive a restricted chow diet of 85% of their ad lib feed per day, and
their weights were not allowed to drop below 90% of their ad lib feeding weight. Any
animal unable to retrieve 9 pellets total in each forepaw by training termination was
excluded from functional analysis.
Montoya staircase functional testing post-stroke took place for 3 days in the darkphase, and was always preceded by an
overnight fast. Specifically, testing took
place on days 8-10 and 29-31 poststroke. The testing subjects' diets were
restricted to 10 grams total between the
drug vehicle and rat chow. Any animal
unable to retrieve a single pellet during

	
  

Figure	
  12.	
  Forelimb	
  Asymmetry	
  
functional	
  test	
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post-stroke tests was excluded from functional analysis.
Forelimb Asymmetry Functional Test
This test examines motor deficits within each forepaw by counting the number of
wall-contacts the rat subject makes with each paw individually over a 5-minute time
period. The animal was placed into a clear, 9 inch ID acrylic tube, and the subject was
attracted to the maple extract painted 14 inches from the inside-bottom of the cylinder
(see Figure 12). To ensure results were accurate, wall contacts were counted from a video
recording made of each test played back in slow-motion.
Euthanization and Cardioperfusion
Animals subjects were euthanized 32 days post-stroke induction. The anesthetic
used was 100 mg/kg pentobarbital (Euthasol), administered via intraperitoneal injection.
Euthasol was chosen because it puts animals in the surgical plane relatively quickly,
maintains cardiac function to prevent clotting during perfusion, and enables subjects to
display the “cardioperfusion dance” (described below). Once the anesthesia was
appropriately set, cardioperfusion was established with a minimum of 150 mLs PBS
solution. The PBS solution was then stopped and almost instantly the neural fixative
solution was perfused. The fixative used was 4% paraformaldehyde in PBS, and a
minimum of 150 mLs was circulated. A successful cardioperfusion is initially gauged by
a pale discoloration of the liver as well as a “cardioperfusion dance” in which the rat's
limbs move around in a swimming motion caused by fixative induced skeletal muscle
contractions.
Immunohistochemistry
Following cardioperfusion, all collected rat brains are immediately placed in 4%
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paraformaldehyde in PBS blocking solution at 5°C. The brains are postfixed for 24 hours
in this solution before being transferred into 30% sucrose in PBS at 5°C for 3 days.
50 micrometer thick sections were sliced from each rat brain ensuring the entire
infarct was present somewhere in between the first and last section taken. 1 out of every 3
sections was retained in PBS solution for estimation of infarct volume.
Group 2 Long Evans and Group 1 Sprague Dawley rat infarct section were first
dried on slides, and then labeled using Nissl stain. This stain labels nissl bodies found
primarily in the nucleus in the cortex, allowing damaged cells due to stroke to be shown
in contrast to the remainder of the undamaged section. Stained sections then underwent a
destaining and dehydration process. Slides were dipped in these solutions sequentially:
Cresyl Violet (Nissl) stain (15 min), Distilled water (5 min), 70% ethanol (5 min), 95%
ethanol (5 min), 100% ethanol (5 min), 100% ethanol (5 min), Xylene (5 min), Xylene (5
min). Nissl stain was created using 2.5 grams of Cresyl Violet dissolved in a 500 mL
solution made of water (300mL), 1M Na acetate (30 mL), and 1M acetic acid (170 mL).
The permanent mordant DPX was used to cover-slip the slides.
The retained sections from Group 2 Sprague Dawley rats were transferred from
the PBS solution into PBS containing 1% Triton and 3% donkey serum (serum from host
of secondary antibody). These sections are reacted with 8-hydroxyguanosine primary
antibody (1:500 dilution) overnight for about 16 hours (antibody purchased from
Abcam® company). 8-hydroxyguanosine is a marker of oxidative stress in DNA; it is a
modified DNA base damaged from hydroxyl radicals produced by oxidative stress
(Abcam, 2008). The secondary antibody used was a fluorescence label: Donkey Antimouse IgG Rhodamine-X-Red (1:100 dilution), which was interacted with washed
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sections for 2.5 hours. After a final set of washes, the stained sections were mounted onto
gel-subbed slides and cover-slipped using Vectashield® to prevent photo-bleaching.
Image Capture and Infarct Volume Calculation

Figure	
  13.	
  Infarct	
  tracing	
  using	
  ImageJ	
  to	
  calculate	
  infarct	
  area	
  of	
  a	
  section.	
  	
  
Spot	
  Scope	
  image,	
  Nissl	
  stain	
  (left);	
  Confocal	
  image,	
  8-‐hydroxyguanosine	
  stain	
  (right)	
  
The cortical stroke infarct was located and imaged using both the Olympus Epi
Fluorescence Spot Scope (for Nissl stained sections) and Olympus FV300 Confocal
Microscope (for 8-hydroxyguanosine stained sections). In cases of large infarcts, multiple
images were captured and montaged using Adobe Photoshop.
Individual infarct areas for each section were calculated using the NIH	
   ImageJ
Program. To calculate an infarct volume, the following steps were followed: 1) Trace the
infarct area using ImageJ (see Figure 13); 2) Calculate the Infarct Area (mm2); 3)
Multiply: Infarct Area (mm2) X 0.05 (mm) Section Width = Section Volume; 4) Multiply
each Section Volume X 3 = Total Section Volume; 5) Sum: ΣTotal Section Volumes =
Infarct Volume.
The student t-test was used to analyze the infarct volumes.
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Statistical Analysis
Two Way Repeated Measures ANOVA was used to analyze the functional data
for both Forelimb and Montoya Staircase tests. Post-hoc test varied. To analyze
differences in infarct volume, t-test was used for two groups or ANOVA for three groups.
Exclusions
As mentioned previously, any rat subject that failed to fully ingest the drug
vehicle for 3 days was removed from analysis. Also, subjects that failed to successfully
retrieve 9 pellets with each paw during Montoya Staircase training were removed. Deficit
Criteria: Any subject that does not display a minimum 15% functional deficit in
Forelimb Asymmetry and 15% functional deficit in Montoya Staircase was excluded
from the study. 	
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RESULTS
Experimental Design Summary
Three different post-stroke medicated treatments were tested; Drug combination
1: 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin and 20 mg/kg ascorbic acid (FSA); Drug
combination 2: 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin (FS); Vehicle control (C). In
addition to testing drug combinations, two different sets of stereotactic coordinates were
used during endothelin injection. Rats were divided into two groups; Group 1: (AP: 0.0
mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm); Group 2: (AP: 0.0 mm, ML: 2.5mm) and (AP +2.3; ML -2.5 mm). The two stocks tested were Sprague Dawley (SD)
and Long Evans (LE). The infarct volume of each subject was measured after the 31-day
treatment regimen post-stroke and subsequent euthanization on day 32.
Forelimb Motor Functional Testing
Data was collected for all rats in the study using both the Forelimb Asymmetry
and Montoya Staircase functional tests (see Tables 1 and 2). Rats were subject to
Montoya Staircase testing two times during the post-stroke study, aside from pre-stroke
training. Forelimb Asymmetry testing occurred three times during the post-stroke study.
After analyzing post-stroke data, I used Montoya Staircase testing data to study
deficit correlations with infarct volume because Forelimb Asymmetry data showed
spontaneous recovery in control rats, with significant improvement in % of contralateral
limb use 16 and 28 days post-stroke (PS) (see Figure 14). Rapid recovery could be due to
the small infarct volumes induced, but this was only seen in Forelimb Asymmetry data.
22

Figure 14. Forelimb Asymmetry Test Results. Error bars represent SEM. # indicated
P<0.05 using Repeated Measures ANOVA and post hoc test.
Results analyzed from a previous study conducted in our lab by Kailee Haggerty
f
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Figure 15. Infarct Volume Comparison: Group 2 LE rats. Treatment groups: FSA
(Fluoxetine, Simvastatin, Vit. C), Control. Error bars - SEM
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Effect of Post-stroke Drug-treatment
Post-stroke medical treatments were compared by infarct volume in Group 2
Long Evans rats. The treatment groups tested were FSA and the vehicle control (see
Figure 15). No significant difference was found between an FSA mean infarct volume of
5.4696 m3 (SEM = 1.6762) and Control mean infarct volume of 9.6310 m3 (SEM =
2.6527) (p = 0.221; T-test).
Group 2 LE rat treatment groups were separated by rats that met a poststroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed
Montoya training criteria. FSA and Control groups were separately evaluated, and then
these two groups were further divided by criteria fulfilled. In Group 2 LE, FSA rats, all
rats that met training criteria also met deficit criteria (see Figure 16). The Met All
Criteria mean infarct volume (6.7380 mm3) was found to be relatively similar to the
Training Criteria Not Met mean infarct volume (4.2013 mm3). Statistical analysis could
not be conducted with sample sizes smaller than N = 3. Also, because rats that did not
meet training criteria were excluded from the study and therefore functional testing, the
degree of functional deficit caused by the infarcts could not be determined.
The Group 2 LE, Control group was divided by criteria fulfilled (see Figure 17).
Again, all rats that met training criteria in this group also met the deficit criteria. The Met
All Criteria mean infarct volume (7.5866 mm3) was relatively similar to the Training
Criteria Not Met mean infarct volume (13.7198 mm3). Statistical analysis could not be
conducted because of small sample size; functional deficit caused by infarcts in the
Training Criteria Not Met group could not be determined.
Overall findings suggest that infarct volume does not correlate with post-stroke
25

Figure 16. Infarct Volume Comparison: Group 2 LE, FSA rats.
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Figure 17. Infarct Volume Comparison: Group 2 LE, Control rats.
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drug treatment. Data showed that mean infarct volumes in rat treatment groups that met
and did not meet criteria were relatively similar. Conclusions could not be drawn
regarding a correlation between infarct size and functional deficit attained because there
were no rats that met training criteria but failed to meet deficit criteria.
A few problems were encountered with the LE rat stock used in these
experiments. These rats were observed to have a high mortality rate of 25-30% during
endothelin-induced stroke surgery coupled with a problem in reliably ingesting the drug
vehicle (significantly different from other rats stocks or strains tested; Chi squared test).
Furthermore, LE adult rats at 10-12 months were relatively unavailable commercially.
For these reasons, Sprague Dawley rats were used for the remainder of testing. Poststroke medical treatments were compared by infarct volume in Group 2 SD rats. The
treatment groups tested were FSA and the vehicle control (see Figure 18). No significant
difference was found between an FSA mean infarct volume of 0.8835 mm3 (SEM =
0.2165) and Control mean infarct volume of 0.9275 mm3 (SEM = 0.1864) (p = 0.373; Ttest).
The Group 2 SD rat treatment group was separated by rats that met a poststroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed
Montoya training criteria. Each treatment group was looked at individually and each
group based on criteria fulfilled was compared (see Figure 19). When examining Group 2
SD, FSA rats, no significant difference was found between the Met All Criteria mean
infarct volume (1.0630 mm3; SEM = 0.6876), Deficit Criteria Not Met (0.6566 mm3;
SEM = 0.2576), and Training Criteria Not Met (1.1580 mm3; SEM = 0.3477) (p = 0.390;
One-way ANOVA). Group 2 SD, Control rat treatment group was separated by rats that
28

Figure 18. Infarct Volume Comparison: Group 2 SD rats. Treatment groups: FSA
(Fluoxetine, Simvastatin, Vit. C), Control. Error bars - SEM
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Figure 19.
Infarct Volume Comparison: Group 2 SD, FSA rats.
Error bars - SEM.
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Figure 20.
Infarct Volume Comparison: Group 2 SD, Control rats.
Error bars - SEM. Middle bar (Deficit Criteria Not Met has no error bar).
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met a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats
that failed Montoya training criteria (see Figure 20). No significant difference was found
between the Met All Criteria mean infarct volume (1.0425 mm3; SEM = 0.4791), Deficit
Criteria Not Met (0.6110 mm3), and Training Criteria Not Met (0.9708 mm3; SEM =
0.0864 mm3) (p = 0.281; One-way ANOVA).
Overall findings for Group 2 SD rats suggest that infarct volume does not
correlate with post-stroke drug treatment. Results show that mean infarct volumes in rat
groups Met All Criteria versus rats were relatively similar to rat groups Deficit Criteria
Not Met. This implies that a lack of forelimb motor deficit in some rats was not caused
by a faulty endothelin injection, but was rather due to a mislocation of the infarct relative
to the forelimb motor cortex.
Effect of Rat Stock on Infarct Volume
Group 2 SD and LE rats treatment groups were also compared against one
another, according to infarct volume, to test for a correlation in the infarct induced with
rat stock used (see Figure 21). As previously described, the two treatment groups tested
in Group 2 LE and SD rats were FSA and the vehicle control. These findings find a
significant difference in mean infarct volume between rats stocks in both the FSA (LE =
5.4696, SEM = 1.6762; SD = 0.8835, SEM = .2165; p = 0.025, T-test) and Control
groups (LE = 9.6310, SEM = 2.6527; SD = 0.9275, SEM = 0.1864; p = 0.014, T-test). SD
rats were found to have smaller infarcts induced within both treatment groups.
The same comparison as seen in Figure 21 was made, but only using rats that met
a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see Figure
22). Again, the mean infarct volume of FSA-LE (6.7380 mm3; SEM = 1.0571) was found
32

Figure 21.
Infarct Volume Comparison: Group 2 LE vs SD rats ;Treatment groups: FSA
(Fluoxetine, Simvastatin, Vit.C), Control. Error bars - SEM.
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Figure 22.
Infarct Volume Comparison: Group 2 LE vs SD rats. Treatment
groups: FSA (Fluoxetine, Simvastatin, Vit.C), Control. Error bars - SEM.
Excluded – Subjects that failed to meet forelimb motor deficit criteria
LE bars with N = 2 have no error bars
Excluded – Subjects that failed to meet forelimb motor deficit criteria
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to be significantly less than that of FSA-SD (1.0630 mm3; SEM = 0.6876) (p = 0.017, Ttest). Though the mean infarct volume of Control-LE (7.5866 mm3; SEM = 2.9278)
seems clearly smaller than that of Control-SD (1.0425 mm3; SEM = 0.4791), this
difference was not found to be significant (p = 0.133, T-test), most likely due to a small
sample size and large variability in the infarct volumes.
Overall, these findings suggest that endothelin-induced cortical strokes produce a
significantly larger infarct volume in LE rats in comparison to SD rats. The difference
seen here can be attributed to the greater number of cerebral collateral vessels found in
SD rats versus LE rats (Ginsberg, 1989). Collateral vessels allow blood flow to
circumvent an infarct, thus reducing the total amount of tissue damage caused by the
ischemic attack.
In order to create “LE-sized” infarct volumes within SD rats, different cortical
injection coordinates must be used in SD rats. Therefore, AP coordinates for one
injection site were moved, relative to bregma, to +1.5 (Group 1) instead of +2.3 (Group
2). Thus the two endothelin injection sites were closer to each other for this final group of
subjects – Group 1 SD rats.
Effect of Post-stroke Drug Treatment
Post-stroke medical treatments were compared by infarct volume in Group 1 SD
rats. The treatment groups tested were FSA, FS, and the vehicle control (see Figure 23).
No significant difference was found between any of the groups – an FSA mean infarct
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volume of 3.4561 mm3 (SEM = 0.5463), an FS mean infarct volume of 2.6579 mm3
(SEM = 0.5361), and a Control mean infarct volume of 2.8176 mm3 (SEM = 0.8531) (p
= 0.612; One-way ANOVA). The Group 1 SD Control group infarct volumes were

Figure 23.
Infarct Volume Comparison: Group 1 SD rats. Treatment
groups: FSA (Fluoxetine, Simvastatin, Vit.C), FS (Fluoxetine, Simvastatin),
Control. Error bars - SEM.
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Figure 24.
Infarct Volume Comparison: Group 1 SD, FSA rats.
Error bars - SEM. Middle and right bars with N=2 have no error bars.
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Figure 25.
Infarct Volume Comparison: Group 1 SD, FS rats.
Error bars - SEM. Right bar, with N=1, has no error bar.
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measured outside of this study by Kailee Haggerty, M.S. using 8-hydroxyguanosine
instead of Nissl stain.
Group 1 SD rat treatment group was separated by rats that met a post-stroke/prestroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed Montoya
training criteria. Each treatment group was looked at separately, and then further divided
by criteria fulfilled. When examining Group 1 SD, FSA rats, groups were found to be
relatively similar between the Met All Criteria mean infarct volume (3.7943 mm3; SEM =
0.7061), Deficit Criteria Not Met (1.6319 mm3), and Training Criteria Not Met (3.9277
mm3) (see Figure 24).
In Group 1 SD, FS rats, mean infarct volumes were again found to be relatively
similar along all groups (see Figure 25). Mean infarct volume for Met All Criteria was
2.4364 mm3 (SEM = 0.9031), mean infarct volume for Deficit Criteria Not Met was
2.5809 mm3 (SEM = 0.7790), and the mean infarct volume for Training Criteria Not Met
was 4.0733 mm3. Comparing the Met All Criteria and Deficit Criteria groups directly,
these groups were found to have no significant difference (p = 0.439, T-test).
Overall, findings suggest that infarct volume does not correlate with post-stroke
drug treatment in Group 1 SD rats. Furthermore, results show that mean infarct volumes
in rat groups Met All Criteria were relatively similar to rat groups Deficit Criteria Not
Met.
Effect of Stereotactic Coordinates on Infarct Volume
Stereotactic coordinates between Group 1 and Group 2 SD rats were varied at one
injection site in AP coordinates, +1.5 and +2.3 respectively. The FSA drug group was
used in both groups in this study; therefore, these groups were used to analyze the effect
39

Figure 26.

Infarct Volume Comparison: Group 1 and 2, SD, FSA rats
Group 1 – AP: 0.0 and +1.5 mm; Group 2 – AP: 0.0 and +2.3.
Error bars - SEM.
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Figure 27.

Infarct Volume Comparison: Group 1 and 2, SD, FSA rats
Group 1 – AP: 0.0 and +1.5 mm; Group 2 – AP: 0.0 and +2.3
Excluded – Subjects that failed to meet forelimb motor deficit criteria
Error bars - SEM.
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of stereotactic coordinates on infarct volume (see Figure 26).
The Group 1, SD, FSA mean infarct volume (3.4561 mm3; SEM = 0.5463) was
found to be significantly larger than the Group 2, SD, FSA mean infarct volume (0.8835
mm3; SEM = 0.2165) (p < 0.001).
Group 1 and Group 2, SD, FSA rats were compared again, except only using rats
that met a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see
Figure 27). Group 1, SD, FSA rats were found to have a nearly significantly larger mean
infarct volume (3.7943 mm3; SEM = 0.7061) than that of Group 2, SD, FSA rats (1.0630
mm3; SEM = 0.6876) (p = 0.057).
These results suggest that Group 1 coordinates [(AP: 0.0 mm, ML: -2.5 mm) and
(AP +1.5 mm; ML: -2.5 mm)] create larger infarcts than Group 2 coordinates [(AP: 0.0
mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm)] in SD rats. Larger infarcts can be
attributed to the fact that Group 1 coordinates are closer to each other than Group 2
coordinates. Closer injection coordinates may allow the initial growing endothelininduced infarcts to coalesce more readily and therefore disrupt a greater number of brain
vessels, thus creating a larger infarct.
Montoya Deficit vs. Infarct Volume
Finally, Montoya Deficit (1 - % Prestroke performance) was plotted against
infarct volume in all SD rats that met a post-stroke/pre-stroke deficit criteria of 0.85 (15%
forelimb motor deficit) (see Figure 28) using data from post-stroke day 9. A linear
regression was calculated using these data points (r2 = 0.632137).
Montoya Deficit was again plotted against infarct volume in all SD rats that met a
post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see Figure
42

29) using data from post-stroke day 30. A linear regression was calculated using these
data points (r2 = 0.708356).
These linear correlations, though only moderately strong, suggest that rat subjects
who sustained an adequate forelimb motor cortex deficit to meet criteria had infarcts that
hit at least a portion of the motor cortex. Those animals with larger infarcts that
correlated with larger deficits could be inferred to have hit more of the motor cortex.
Those animals with smaller infarcts could be inferred to have hit a smaller portion of the
motor cortex for forelimb.
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Figure 28.

Montoya Deficit vs Infarct Volume: Group 1 and 2 SD rats
PSD ~ 9; Linear regression shown: r2 = 0.632137
Excluded – Subjects that failed to meet forelimb motor deficit criteria
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Figure 29.

Montoya Deficit vs Infarct Volume: Group 1 and 2 SD rats
PSD ~ 30; Linear regression shown: r2 = 0.708146
Excluded – Subjects that failed to meet forelimb motor deficit criteria
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Table 1.
Group 1 Functional Test Data and Deficit Results
Rat #
411
412
413
414
415
417
418
419
420
421
422
423
424
426
427
428
429
430
431
432
433
434

Infarct Volume
(mm3)
^4.21545
^3.64005
&0.34875
*1.5177
*3.67845
*5.8479
*1.55325
^4.07325
*0.90465
&0.717
*2.6631
*1.21305
&1.88025
&3.74085
&3.98535
*2.52285
*2.6856
*5.7639
*3.147
*7.7133
&2.91495
*3.3255

Group
FSA
FSA
FSA
FSA
FSA
FS
FS
FS
FS
FS
FS
FS
FS
FS
FS
FSA
FSA
FSA
FSA
FSA
FSA
FSA

Rat
Stock
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD

Montoya
Staircase
^PSD 9
PTC-not met
PTC-not met
1
0.8235
0.4
0.4118
0.6471
PTC-not met
0.7429
0.8947
0.7778
0.7941
1
0.8824
1.5833
0.7222
0.7059
0
0.625
0.375
0.9412
0.6

Montoya
Staircase
PSD 30

0.7647
0.6
0.2941
0.8823
0.8
0.7368
0.8889
0.7647
1
1.0588
1.1667
0.7778
0.7059
0.2105
0.6875
0.4375
0
0.5333

Forelimb
Asymmetry
PSD 3
0.8521
0.5592
1.007
1.0447
0.5085
0.613
0.7743
0.7367
0.7996
0.8328
0.9627
1.209
0.7212
0.8933
0.7145
0.5455
0.875
0.6635
0.7274
0.7262
0.6929
0.6201

Forelimb
Asymmetry
PSD 28
1.0542
0.8652
1.0444
1.0755
0.54901
0.7783
0.9508
0.9679
1.0543
0.8678
1.1828
1.1717
0.7549
0.8931
0.8145
0.7850
1.1683
0.6917
0.9463
0.8732
0.9311
0.6360

Group 1 Cortical Injection Coordinates: (AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm)
PSD: Post-stroke Day
PTC: Pre-stroke Testing Criteria. Rats unable to retrieve a minimum of 9 pellets with each forepaw during
pre-stroke testing were excluded from the study
FSA: Fluoxetine, Simvastatin, Ascorbic Acid; FS: Fluoxetine, Simvastatin
* All Criteria Met
^ Training Criteria Not Met
& Deficit Criteria Not Met
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Table 2.
Group 2 Functional Test Data and Deficit Results
Rat
#
403
404
406
407
408
409
410
450
451
452
453
455
456
457
458
460
461
462
463
464
465
467
468
469
2470
471
472
473
474

Infarct
Volume
(mm3)
*5.68095
*10.5144
^13.71975
*7.79505
^7.74
*4.65885
^0.6625
^0.7758
*2.45655
*2.43735
^0.7563
&0.20955
^0.91155
^1.07115
&1.88385
*0.5616
&0.6051
*0.78675
^1.8522
*0.36525
*0.3351
&0.60855
&0.5097
*0.41655
^1.1442
^0.846
&0.7122
&0.471
&0.16125

Group
FSA
C
C
FSA
FSA
C
FSA
FSA
C
FSA
C
FSA
C
C
FSA
C
FSA
C
FSA
C
FSA
FSA
C
FSA
C
FSA
C
FSA
FSA

Rat
Stock
LE
LE
LE
LE
LE
LE
LE
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD

Montoya
Staircase
PSD 9
0.3571
0.2616
PTC-not met
0.6842
PTC-not met
0.2
PTC-not met
PTC-not met
0.8333
0
PTC-not met
0.925
PTC-not met
PTC-not met
0.8667
0.7
0.8947
0.825
PTC-not met
0.8333
0.8095
0.95
0.8889
0.7059
PTC-not met
PTC-not met
0.95
0.9474
0.9474

Montoya
Staircase
PSD 30
0
0.473684211
0.526315789
0.2

0.8889
0.5556
0.7

0.9333
0.75
0.6842
0.9
0.8333
0.9524
0.9
0.8333
0.7647

0.9
0.8421
0.9474

Forelimb
Asymmetry
PSD 3
n/a
n/a
0.7726
0.9257
0.9357
0.7286
1.181
0.8426
0.7705
0.6588
0.6445
1.1362
0.7101
1.1126
0.7174
0.7342
0.6762
0.5504
0.8333
1.0291
0.8837
0.7269
0.8781
0.9332
0.8303
0.9193
1.0674
1.088
0.9469

Forelimb
Asymmetry
PSD 28
n/a
n/a
0.8148
0.9785
0.9682
0.4659
1.5423
0.7977
0.7611
0.8850
0.9014
1.0299
0.8587
1.001
0.9107
0.8743
0.9498
0.6518
1.0029
1.1623
0.8165
0.9660
0.9553
0.8885
0.6727
1.0178
1.1417
1.1146
1.0943

Group 2 Cortical Injection Coordinates: (AP: 0.0 mm, ML: -2.5 mm) and (AP +2.3 mm; ML: -2.5 mm)

C:Control
* All Criteria Met
^ Training Criteria Not Met
& Deficit Criteria Not Met
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DISCUSSION
Montoya Staircase vs. Forelimb Asymmetry
Animal subjects were gauged on whether or not an adequate contralateral forepaw
motor deficit was attained based on Montoya Staircase functional testing. As mentioned,
Forelimb Asymmetry functional testing was also conducted for all rats. Forelimb
Asymmetry data could not be used for this study, however, because of the spontaneous
recovery observed on post-stroke days 16 and 24 (see Figure 14) with some of the
infarcts in Sprague Dawley rats.
I attributed this spontaneous recovery of both control and drug treatment groups
to the very small infarcts seen post-euthanization in rat subjects, especially Group 2
Sprague Dawley rats. Smaller infarcts can potentially have a greater chance of preserving
the specific forelimb function tested in the Forelimb Asymmetry apparatus. The Forelimb
Asymmetry test is not as rigorous a functional test as the Montoya Staircase – it involves
less complex motor function to complete the task. Therefore, a valid hypothesis could be
that Montoya function (grasping and holding) can be more easily altered and less easily
preserved than Forelimb Asymmetry function. Further testing using a greater number of
Sprague Dawley rats with larger endothelin-induced infarcts must be conducted to see if
this theory explains the spontaneous recovery.
Contralateral Forepaw Deficit Criteria
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Rats had to sustain a 15% contralateral forepaw deficit in Montoya Staircase functional
testing to fulfill deficit criteria. This deficit criteria was lowered from an original 20%
deficit because many animals did not sustain an adequate deficit to meet this higher
criteria. This could again be attributed to the smaller infarcts induced in Group 2 Sprague
Dawley rats.
As the drug-treatment data showed, infarct volumes were relatively similar in
groups that met and did not meet deficit criteria (see Figures 19, 20, 24, 25). This led to
the conclusion that an adequate deficit was not attained not because of a faulty endothelin
injection (too little endothelin injected), but rather a mislocation of the injection site
relative to the forelimb motor cortex. A faulty endothelin injection would result in
significantly smaller induced infarcts in those animals not meeting deficit criteria. A
mislocation of the infarct could occur for a number of reasons: Bregma, the reference
point for all coordinates, was not easily identified or was indistinct in some rats; the brain
underneath the rat skulls (and therefore, the reference marks) may have been slightly
misaligned relative to each animal; or the injection needle did not penetrate tissue in a
perfectly vertical plane and thus may have affected a nearby location to the motor cortex.
A small trend may seem to appear in Figures 19, 20, and 24 suggesting that rats
not meeting deficit criteria have smaller infarcts. However, in Figure 19, a p-value of
0.390 clearly indicates no significant difference between any group; in Figures 20 and 24,
the sample size of N < 3 was too small to conduct statistical analysis or draw any
conclusions. Figures 19 and 25 have Deficit Criteria Not Met groups that had an adequate
sample size (N > 2), and in both cases, Deficit Criteria Not Met was found to be clearly
similar to the Met All Criteria group (p = 0.390 and 0.439, respectively).
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Group 2 Long Evans rats had no cases that resulted in rats meeting training
criteria but failing to meet deficit criteria. This could be due to a small sample size (N =
7), which would imply that there was simply not enough of a chance to have an animal
that met training but failed deficit criteria. Another theory, however, could be that more
accurate infarcts hitting the motor cortex, thus inducing an adequate deficit, could be
attained in Long Evans rats. This could be attributed to a potentially less variable brainto-skull alignment, a more distinct bregma reference point, or simply that Long Evans
rats sustained larger infarcts than Sprague Dawley rats. Further testing using a greater
number of Long Evans rats is needed to determine the cause.
Functional tests determining whether or not rats met deficit criteria were
conducted on days 8, 9, and 10 post-stroke. Perhaps conducting this test closer to the day
of stroke induction would show more accurately the amount of deficit induced by stroke
infarct, and would lessen the potential effects of small recovery that may be attained
during the first ten days post-stroke.
Effect of Rat Stock on Infarct Volume
Group 2 coordinates (AP: 0 & +2.3) were initially used for endothelin stroke
induction surgery in Long Evans rats. These coordinates produced adequately large
infarcts in this rat stock. However, our laboratory switched to the Sprague Dawley rat
stock because of the reasons previously mentioned: 1) Sprague Dawley were much easier
to attain commercially, 2) Long Evans rats had a large mortality rate during stroke
surgery while Sprague Dawley had only about a 3% mortality, and 3) Sprague Dawley
rats were shown to ingest the drug vehicle with significantly greater reliability compared
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to Long Evans and Wistar rat stocks in a study conducted by this lab previously (Corbett
et al, Laboratory Animals in press).
Infarcts sustained in Sprague Dawley rats using Group 2 coordinates were
significantly smaller than infarcts sustained in Long Evans rats using Group 2 coordinates
(see Figures 21 & 22). This difference was seen in both FSA and Control groups (p =
0.014 and 0.025 respectively) and was attributed to the lesser number of collateral vessels
found in Long Evans versus Sprague Dawley rats (Ginsberg, 1989; Prieto, 2005). An
occluded vessel may re-route blood flow to smaller surrounding vessels due to increased
pressure from the blockage. If blood has more avenues through which it can continue
flowing to the next major vessel, more tissue volume surrounding the occlusion can be
retained. Greater tissue damage results when blood cannot circumvent an occlusion, thus
creating a larger sustained infarct.
Stereotactic Coordinates for Endothelin Cortical Injection
As mentioned, Group 2 coordinates were first used in Long Evans rats, and then
in Sprague Dawley rats. When it was observed that Sprague Dawley rats sustain much
smaller infarcts using these cortical injection coordinates, our laboratory changed the AP
coordinates so that the two injection sites were closer for the Group 1 Sprague Dawley
rats (Group 1 – AP: 0 & +1.5). The aim was to develop Sprague Dawley infarcts that
mimicked the Long Evans-sized infarcts seen initially. These closer injection coordinates
proved to induce significantly larger infarcts than the farther Group 2 coordinates (see
Figures 26 & 27). An AP coordinate of +1.5 was chosen because this had been
previously shown to be the center of the forelimb motor cortex (Kleim et al., 1996).
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A larger infarct may be induced in coordinates that are closer to one another
because of the greater additive effect of concentration gradients from closer endothelin
injections. As endothelin perfuses away from the injection site through brain tissue, its
total concentration decreases with distance, creating a concentration gradient. When the
injection sites are farther apart, there is a lower total additive concentration when these
gradients intersect, thus fewer vessels are occluded.
A future study may look at this overlapping concentration gradient theory by
moving these closer injection coordinates relative to this “dead-on” forelimb motor
cortex spot of AP +1.5. Group 1 coordinates used AP coordinates of 0 and +1.5, with the
+1.5 being right on the forelimb motor cortex (Kleim et al., 1996). Therefore, the two
perfusing concentration gradients would coalesce next to but not on this “dead-on” spot.
A future study could test AP coordinates of +0.75 and +2.25 (“Group 3”
coordinates), which would contain the dead-on spot right in between and allow the
gradients to intersect at this spot, making it the center of the large “combined” infarct. If
more rats are able to meet deficit criteria using these potential Group 3 coordinates versus
the Group 1 coordinate subjects in this study, this may show that coalescing endothelin
concentration gradients produce one greater infarct that occludes many vessels. If fewer
rats are able to meet deficit criteria, this result would suggest coalescing endothelin
concentration gradients still have a smaller additive effect than a single infarct that is
placed directly on the motor cortex.
The ability of intersecting concentration gradients to occlude vessels depends on
the total endothelin concentration at the edge of the perfusing concentration gradient.
Suppose the edge has half of the total endothelin concentration – this would suggest that
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two additive “edges” intersecting would create a fully concentrated endothelin induced
infarct. Such an infarct would theoretically occlude as many vessels as if there was a
direct endothelin injection into this “edge - intersecting” area. Suppose the perfusing edge
has one-fourth the total endothelin concentration – this would suggest the two additive
“edges” intersecting would sum to only half of the total endothelin concentration. This
infarct would theoretically occlude fewer vessels and maintain more tissue integrity than
if each edge made up half of the total concentration. Essentially, the smaller the
perfusing gradient (or the greater the total concentration on each “edge”), the greater
probability of occluding more vasculature, thus creating a larger infarct.
Furthermore, an observation in this study is that Long Evans rats showed trend
toward recovery in the FSA group versus Control. Group 2 coordinates used here
surrounded the forelimb motor cortex, but were not directly on the “dead-on” forelimb
motor cortex spot of AP +1.5 (Kleim et al., 1996). A theory for why recovery was seen
here could be the fact that the two coalescing endothelin concentration gradients may
damage the tissue in between (forelimb motor cortex), but not completely destroy and kill
it. Images taken to measure the infarct show a clear area beneath the injection site of
destroyed tissue. Damaged tissue can potentially show a higher propensity for recovery in
comparison to tissue that is completely dead.
Montoya Staircase Functional Deficit vs. Infarct Volume
Montoya Deficit (1 – Prestroke function %) was plotted against Infarct Volume
for all Group 1 Sprague Dawley rats that met deficit criteria. Linear trends observed in
Figures 25 and 26 (r2 = 0.632137 and 0.708146 respectively) suggest that greater infarct
volumes result in greater Montoya Deficits in rats that met deficit criteria. Specific points
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to note are rat 430 in Figure 25, and rats 417 and 430 in Figure 26. All three of these data
points show an infarct volume sustained around 6 mm3 and Montoya Deficit of around
0.75 or greater. These infarcts can be determined as “hitting the spot” of the forelimb
motor cortex. Though rat 432 sustained the largest infarct volume of all Group 1 Sprague
Dawley rats that met deficit criteria, it did not sustain the greatest Montoya Deficit. This
difference implies that the rat 432 infarct was not completely within the forelimb motor
cortex. Infarcts such as the one seen with rat 432 may explain why these charts in Figure
25 and 26 do not show a tight correlation (r2 > 0.90) – part of the infarct was not within
the motor cortex, thus creating a large infarct with a relatively smaller Montoya deficit.
Drug Treatment Effects on Infarct Volume
Results showed that the drug combinations FSA (fluoxetine, simvastatin, and
ascorbic acid) and FS (fluoxetine, simvastatin) had no effect on infarct volume when
compared to Control subjects (see Figures 15, 18, and 23). Infarct volumes for all drug
and control groups showed no significant difference in all situations where statistical
analysis could be conducted (N > 2).
One explanation may the difference in active metabolite enantiomers in the brand
name fluoxetine (Prozac) versus the generic brand used in Group 2 Sprague Dawley rats.
Prozac is made up of an approximately 50:50 ratio of R:S fluoxetine enantiomers (Kim,
2004). The active metabolite of these enantiomers is S-norfluoxetine is shown to be at
least 20 times more active than its counterpart R-norfluoxetine (McDonagh et al., 2011;
Kim, 2004). Both R and S-norfluoxetine have been shown to have a half-life of 7 to 15
days, while R and S-fluoxetine have a half-life of 2 to 4 days (Gury et al., 1999). HPLC
analysis conducted after this study showed that generic brand fluoxetine had a 15%
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higher amount of R-fluoxetine and a 15% lower amount of S-fluoxetine in comparison to
brand name Prozac™ (study was conducted by Audrey McGowin – Chemistry Dept. at
Wright State University). This would imply that there is a lower amount of the active
metabolite S-norfluoxetine in the generic fluoxetine used - this may influence the ability
of generic brand fluoxetine to affect motor deficits in Group 2 Sprague Dawley rats
because there is less long-lasting active metabolite build-up in the brain.
Another explanation for the lack of drug effect on infarct volume may simply be
due to the fact that drugs are not offered for voluntary oral administration until 20-26
hours after stroke induction. This time lapse may be too great to influence infarct volume
– perhaps administering drugs sooner could have an effect on the infarct. Further testing
using a shorter time lapse between stroke induction and voluntary oral drug
administration would have to be conducted to see if this hypothesis is valid or if the drugs
were ineffective.
The ability of statins to improve motor deficits in past studies may also be due to
upregulation of VEGF along with the previously described upregulation of BDNF. VEGF
promotes angiogenesis - new vasculature can theoretically help regain function in a
damaged brain. Studies are currently being conducted in Dr. Corbett’s lab to analyze the
influence of angiogenesis on motor recovery in rats.

Conclusion
When endothelin-induced cortical strokes are induced in Long Evans and Sprague
Dawley rats using Group 2 coordinates [(AP: 0.0 mm, ML: -2.5mm) and (AP +2.3; ML -
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2.5 mm)], Long Evans rats are shown to sustain a significantly larger infarct volume in
comparison to the Sprague Dawley rat stock.
Comparing infarct volumes induced by the closer Group 1 cortical injection
coordinates [(AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm)] in
comparison to Group 2 coordinates (see above), the closer Group 1 coordinates were
shown to produce a larger infarct volume in Sprague Dawley rats.
Drug treatment groups FSA (fluoxetine, simvastatin, ascorbic acid) and FS
(fluoxetine and simvastatin) were shown to have no effect on infarct volumes when
compared, respectively, to the vehicle control.
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